Key points are not available for this paper at this time.
Abstract The hypoxia of the tumor microenvironment (TME) seriously restricts the photodynamic therapy (PDT) effect of conventional type‐II photosensitizers, which are highly dependent on O 2 . In this work, a new type‐I photosensitizer (TPE‐TeV‐PPh 3 ) consisting of a tetraphenylethylene group (TPE) as a bioimaging moiety, triphenyl‐phosphine (PPh 3 ) as a mitochondria‐targeting group, and telluroviologen (TeV 2+ ) as a reactive oxygen species (O 2 •− , •OH) generating moiety is developed. The luminescence intensity of TPE‐TeV‐PPh 3 increased significantly after specific oxidation by excess H 2 O 2 in the TME without responding to normal tissues via the formation of Te═O bond, which can be used for monitoring abnormal H 2 O 2 , positioning, and imaging of tumors. TPE‐TeV‐PPh 3 with highly reactive radicals generation and stronger hypoxia tolerance realizes efficient cancer cell killing under hypoxic conditions, achieving 88% tumor growth inhibition. Therefore, TPE‐TeV‐PPh 3 with low phototoxicity in normal tissue achieves tumor imaging and effective PDT toward solid tumors in response to high concentrations of H 2 O 2 in the TME, which provides a new strategy for the development of type‐I photosensitizers.
Sun et al. (Fri,) studied this question.